相关实验视频
Updated: May 5, 2026

14:54
A Controlled Mouse Model for Neonatal Polymicrobial Sepsis
Published on: January 27, 2019
11.0K
儿科败血症的性别差异 - - 一个系统性审查协议
Uchenna Kennedy1, Juliette Moulin2, Luregn J Schlapbach3,4
1Children's Research Center, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032, Zurich, Switzerland. uchenna.kennedy@kispi.uzh.ch.
Systematic reviews
|August 8, 2024
概括
这一系统性审查调查了儿童败血症结果的性别差异. 了解这些差异对于改善败血症儿童的生存率至关重要.
科学领域:
- 儿科重症监护医药 儿科重症监护医药
- 免疫学 免疫学 免疫学
- 流行病学 流行病学
背景情况:
- 儿科败血症是全球儿童死亡的主要原因,每年造成300多万死亡.
- 性别和性别显著影响疾病的结果,成人研究表明雌激素在败血性休克中具有潜在的保护作用.
- 现有研究强调了儿科群体的性别特异性免疫学差异,但对败血症结果的影响仍然未经检查.
研究的目的:
- 系统地评估儿童败血症中性别和生存结果之间的关联.
- 为了确定治疗反应和败血症儿童的疾病进展的潜在性别特异性差异.
主要方法:
- 将对MEDLINE和Embase数据库进行系统的文献搜索.
- 纳入标准包括英语随机试验和队列研究,涉及37周妊娠年龄至18岁的患有败血症,严重败血症或败血性休克的儿童.
- 主要结局是医院死亡率;次要结局包括儿科重症监护室和住院时间.
主要成果:
- 该部分将在研究完成后填写.
结论:
- 预期的结果将揭示性别和儿科败血症结局之间的关系.
- 这些发现可能会指导未来对病理生理学和社会经济因素的研究,这些因素有助于观察到临床结果中的性别差异.
相关概念视频
Sex-linked Disorders
95.2K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
95.2K
Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975
Pharmacokinetics in Pediatric Patients: Drug Distribution
558
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
558
Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
Pharmacokinetics in Pediatric Patients: Drug Excretion
413
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
413

